196 related articles for article (PubMed ID: 27390118)
1. The Relationship between the Methylated Septin-9 DNA Blood Test and Stool Occult Blood Test for Diagnosing Colorectal Cancer in Taiwanese People.
Chen CH; Yan SL; Yang TH; Chen SF; Yeh YH; Ou JJ; Lin CH; Lee YT; Chen CH
J Clin Lab Anal; 2017 Jan; 31(1):. PubMed ID: 27390118
[TBL] [Abstract][Full Text] [Related]
2. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514
[TBL] [Abstract][Full Text] [Related]
3. Colorectal cancer screening: comparison of transferrin and immuno fecal occult blood test.
Chen JG; Cai J; Wu HL; Xu H; Zhang YX; Chen C; Wang Q; Xu J; Yuan XL
World J Gastroenterol; 2012 Jun; 18(21):2682-8. PubMed ID: 22690078
[TBL] [Abstract][Full Text] [Related]
4. Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancer.
Warren JD; Xiong W; Bunker AM; Vaughn CP; Furtado LV; Roberts WL; Fang JC; Samowitz WS; Heichman KA
BMC Med; 2011 Dec; 9():133. PubMed ID: 22168215
[TBL] [Abstract][Full Text] [Related]
5. A simplified, non-invasive fecal-based DNA integrity assay and iFOBT for colorectal cancer detection.
Kalimutho M; Del Vecchio Blanco G; Cretella M; Mannisi E; Sileri P; Formosa A; Pallone F; Federici G; Bernardini S
Int J Colorectal Dis; 2011 May; 26(5):583-92. PubMed ID: 21225430
[TBL] [Abstract][Full Text] [Related]
6. Combined Plasma MicroRNA and Fecal Occult Blood Tests in Early Detection of Colorectal Cancer.
Luo X; Wu Y; Ji M; Zhang S
Clin Lab; 2019 May; 65(5):. PubMed ID: 31115212
[TBL] [Abstract][Full Text] [Related]
7. Comparison of an established simple office-based immunological FOBT with fecal tumor pyruvate kinase type M2 (M2-PK) for colorectal cancer screening: prospective multicenter study.
Shastri YM; Loitsch S; Hoepffner N; Povse N; Hanisch E; Rösch W; Mössner J; Stein JM
Am J Gastroenterol; 2008 Jun; 103(6):1496-504. PubMed ID: 18510609
[TBL] [Abstract][Full Text] [Related]
8. Plasma methylated septin 9: a colorectal cancer screening marker.
Molnár B; Tóth K; Barták BK; Tulassay Z
Expert Rev Mol Diagn; 2015 Feb; 15(2):171-84. PubMed ID: 25429690
[TBL] [Abstract][Full Text] [Related]
9. A multicenter prospective study of immunochemical fecal occult blood testing for colorectal cancer detection.
Lohsiriwat V; Thavichaigarn P; Awapittaya B
J Med Assoc Thai; 2007 Nov; 90(11):2291-5. PubMed ID: 18181309
[TBL] [Abstract][Full Text] [Related]
10. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
[TBL] [Abstract][Full Text] [Related]
11. Stool DNA test targeting methylated syndecan-2 (SDC2) as a noninvasive screening method for colorectal cancer.
Su WC; Kao WY; Chang TK; Tsai HL; Huang CW; Chen YC; Li CC; Hsieh YC; Yeh HJ; Chang CC; Wang JY
Biosci Rep; 2021 Jan; 41(1):. PubMed ID: 33393623
[TBL] [Abstract][Full Text] [Related]
12. Performance of a second-generation methylated SEPT9 test in detecting colorectal neoplasm.
Jin P; Kang Q; Wang X; Yang L; Yu Y; Li N; He YQ; Han X; Hang J; Zhang J; Song L; Han Y; Sheng JQ
J Gastroenterol Hepatol; 2015 May; 30(5):830-3. PubMed ID: 25471329
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of the immunofecal occult blood test for colorectal cancer screening in a large population.
Yang H; Ge Z; Dai J; Li X; Gao Y
Dig Dis Sci; 2011 Jan; 56(1):203-7. PubMed ID: 20458621
[TBL] [Abstract][Full Text] [Related]
14. Colorectal screening using the immunochemical faecal occult blood test kit among the Malaysian cohort participants.
Abdullah N; Abd Jalal N; Ismail N; Kamaruddin MA; Abd Mutalib NS; Alias MR; Mazlan L; Sagap I; Jamal R
Cancer Epidemiol; 2020 Apr; 65():101656. PubMed ID: 31923638
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer.
Church TR; Wandell M; Lofton-Day C; Mongin SJ; Burger M; Payne SR; Castaños-Vélez E; Blumenstein BA; Rösch T; Osborn N; Snover D; Day RW; Ransohoff DF;
Gut; 2014 Feb; 63(2):317-25. PubMed ID: 23408352
[TBL] [Abstract][Full Text] [Related]
16. The factors associated with negative colonoscopy in screening subjects with positive immunochemical stool occult blood test outcomes.
Ting PH; Lin XH; Jiang JK; Luo JC; Chen PH; Wang YP; Hsin IF; Perng CL; Hou MC; Lee FY
J Chin Med Assoc; 2018 Sep; 81(9):759-765. PubMed ID: 29778550
[TBL] [Abstract][Full Text] [Related]
17. Colorectal cancer screening using a stool DNA-based SDC2 methylation test: a multicenter, prospective trial.
Kim CW; Kim H; Kim HR; Kye BH; Kim HJ; Min BS; Oh TJ; An S; Lee SH
BMC Gastroenterol; 2021 Apr; 21(1):173. PubMed ID: 33858326
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic Value and Clinical Significance of Methylated SEPT9 for Colorectal Cancer: A Meta-Analysis.
Hu J; Hu B; Gui YC; Tan ZB; Xu JW
Med Sci Monit; 2019 Aug; 25():5813-5822. PubMed ID: 31378778
[TBL] [Abstract][Full Text] [Related]
19. Early detection of colorectal cancer based on presence of methylated syndecan-2 (SDC2) in stool DNA.
Han YD; Oh TJ; Chung TH; Jang HW; Kim YN; An S; Kim NK
Clin Epigenetics; 2019 Mar; 11(1):51. PubMed ID: 30876480
[TBL] [Abstract][Full Text] [Related]
20. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test.
Koga Y; Yamazaki N; Yamamoto Y; Yamamoto S; Saito N; Kakugawa Y; Otake Y; Matsumoto M; Matsumura Y
Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1844-52. PubMed ID: 23950216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
